- 1 Introduction
- 2 The Lipid Hypothesis
- 3 Classification
- 4 Correlations
- 5 Epidemiology
- 6 Causes
- 7 Presentation
- 8 When to treat
- 9 Goals of treatment
- 10 Non-pharmacological interventions
- 11 Medical Agents
- 12 Pregnancy
- 13 Dietary agents affecting cholesterol
- 14 Familial Hypercholesterolaemia
- 15 Elevated Triglycerides
- 16 References
Dyslipidaemia (often interchangeably used with hyperlipidaemia) describes raised levels of cholesterol in the blood. This is significant because it is associated with increased risk of cardiovascular disease.
The lipid hypothesis suggests (and is strongly supported by epidemiological studies) that elevated levels of plasma cholesterol causes coronary artery disease as a result of pathological changes in artery walls.
Lipid lowering therapy reduces the incidence of stroke and coronary artery disease.
In particular, low density lipoprotein (LDL) levels (“bad cholesterol”) are strongly correlated with coronary artery disease, whilst high density lipoprotein (“good cholesterol”) is protective.
Elevated cholesterol is typically discovered in screening blood tests. The decision to treat depends on multiple factors, which as usually assessed using a cardiovascualr scoring system, such as QRISK3🇬🇧 or CVDCHECK🇦🇺.
Statins are the mainstay of treatment. Other lipid lowering drugs are more controversial – such as fibrates – as although they lower measurable cholesterol levels, they have not been associated with a reduction in cardiovascular disease
The Lipid Hypothesis
Historically the management of raised cholesterol is a controversial topic – “the lipid hypothesis” is still challenged in some quarters even today. The landmark “Scandinavian Simvastatin Survival Study (1994) – aka “4S trial” proved survival benefit for lipid lowering therapies.
- Multiple other studies have also shown this benefit – including the following trials; PLACI, PLACII, ACAPS, KAAPS, REGRESS
- The INTERHEART study suggested that 45% of MIs are due to dyslipidaemia
Dyslipidaemia refers to a state of an abnormal lipid profile in the blood. Can be:
- Abnormally high triglycerides
- Abnormally high cholesterol. Can be:
- Total cholesterol – TChol
- Low-density lipoprotein cholesterol – LDL-C
- Abnormally high triglycerides and cholesterol
- Abnormally low high-density lipoprotein – HDL-C
- This is a risk factor for cardiovascular disease regardless of total cholesterol
Technically hyperlipidaemia refers only to increased levels of triglycerides and cholesterol and as such does not include reference to HDL-C. However in practice, the terms dyslipidaemia and hyperlipidaemia are often used interchangeably.
- Risk increases with the degree of cholesterol elevation
- 90% risk of cardiovascular disease in patients with total cholesterol >7.8mmol/L
- 10% reduction in cholesterol gives a 20% reduction in cardiovascular disease risk after 3 years
- Risk of cardiovascular disease particularly high in patients with high LDL and low HDL
- LDL:HDL radio of >4, or HDL <1mmol/L indicates high risk
- Triglycerides >10mmol/L associated with pancreatitis
- LDL reduction with statin therapy reduces MI, stroke, death, and need for revascularisation therapies
- Extremely common in developed nations. In the UK almost two thirds of the adult population has a cholesterol >5.2 mmol/L. Mostly as a result of lifestyle and genetic factors
- Familial hypercholesterolaemia (FH) is a specific genetic disease that causes elevated cholesterol, affecting about 1 in 500 individuals
- Usually heterozygous
- Homozygous disease is extremely rare
- Consider this diagnosis in anyone with a total cholesterol of >7.5 mmol/L
- Associated with a 4x increased risk on cardiovascular disease
Most cases are related to a combination of lifestyle and genetic factors. It is aslo important to consider secondary causes:
- Anorexia nervosa
- Alcohol excess
- Liver disease
- Renal disease
- Thiazide diuretics
- Combined oral contraceptive pill
Usually discovered incidentally on screening.
Levels are measured with a blood sample. A fasting sample is no longer routinely recommended – triglycerides may be falsely elevated in a non-fasting sample, but levels of total cholesterol, HDL-C and LDL-C are not thought to be significantly affected.
It is recommended to have two separate samples at different times to confirm the diagnosis.
- One of these should be fasting
Consider specialist referral for patients with a total cholesterol >20 mmol/L. Levels of >10 mmol/L are associated with an increased risk of pancreatitis. Patients with these levels often have underlying familial hypercholesterolaemia.
Any patient with raised cholesterol should also have:
- Fasting blood glucose – to exclude diabetes as a cause
- Renal function – to exclude CKD as a cause
- LFTs – to rule out liver disease as a cause, and because statin may be contraindicated if AST is >3x the upper limit of normal
- TSH – to rule out myxoedema (hypothyroidism)
When to treat
Treatment should not be based purely on lipid levels. Typically, levels are used in association with a cardiovascular disease risk calculator (e.g. QRISK3🇬🇧 or cvdcheck.org.au🇦🇺) to know when it is appropriate to treat. These calculators use multiple risk factors, including age, gender, blood pressure, smoking history, left ventricular function (if known) and history of diabetes. The basic principles of these calculators involve treating patients with:
- Known cardiovascular disease and total cholesterol >4mmol/L
- High risk patients with total cholesterol >6.5mmol/L OR total cholesterol >5.5mmol/L and HDL <1mmol/L
- Familial hypercholesterolaemia
- FHx of significant cardiovascular disease – first degree relative first diagnosed with cardiovascular disease at <60
- Peripheral vascular disease
- HDL <1mmol/L in ANY patient
In the example above (cvdchech.org.au – recommended in Australia) – patients should be treated medically when their 5-year risk exceeds 15%, and considered for medical treatment between 10-15% if they have failed or are unwilling to engage with lifestyle interventions.
Be aware that the CVDCHECK calculator and many similar alternatives may underestimate risk – particularly as they do not take family history into account – and it may be necessary to make a clinical judgment in cases of a strong family history as described above.
- QRISK3 is more in-depth and includes this among st other factors
Also be aware that the calculator can overestimate the risk on elderly men with no risk factors (purely based on age and gender) and may lead to over treatment in this age group.
Refer patients with any of the below for investigation for familial hypercholesterolaema:
- Total cholestoler >8mmol/L
- Total cholesterol >6mmol/L with FHx of premature ischaemic heart disease
- ‘Premature” defined as – age of onset <55 in men or <60 in women
- Known FHx of a genetic lipid disorder
Goals of treatment
- Total cholesterol <4.0 mmol/L
- HDL-C ≥1.0 mmol/L
- LDL-C <2.0 mmol/L
- TG <2.0 mmol/L
In familial hypercholesteolaemia
- Aim to reduce LDL-C by 50%
Cholesterol levels can be re-checked 6 weeks after an intervention.
Dietary cholesterol accounts for between 10-40% of total cholesterol levels. Specific foods causing elevated cholesterol (e.g. eggs and butter) are probably less important than was previously thought, however the overall quality of the diet is still important.
- Regular exercise
- Smoking cessation
- Alcohol intake <20mg daily (<2 standard drinks, and x2 alcohol-free days per week)
- Weight loss
- Advise of suggest waist measurements for minimising cardiovascular disease risk (<94cm for men and <80cm for women). This risk factor is independent of weight
- Diet advice: aim for plant based, whole food diet. Minimise animal product and processed food intake. “Eat not too much, mostly plants”
- Reduce animal fat intake – meat AND dairy
- Diet high in vegetables and other plant based foods
- Complex carbohydrates
- Avoid deep fried food and “fast foods”
- Steam and grill foods instead of frying
- Avoid snacks heavy in calories (e.g. biscuits, cakes)
- Eat fish at least twice per week
- Can have a measurable effect in cholesterol in 6-8 weeks
- Continue for at least 6 months before considering drug therapy, except in high risk patients
Statins – e.g. atorvastatin, rosuvastatin, simvastatin
- HMG-CoA reductase inhibitors
- Adverse effects
- Myalgias (most common)
- GI upset
- Abnormal LFTs
- Do baseline LFTs and CK
- Repeat at 4-8 weeks
- Recommended to repeat every 6 weeks for 6 months after initiation of therapy
- Ezetimibe 10mg daily
- Often used if statin not tolerated
- Ezetimibe + statin
- Often used if statin alone is not achieving control of cholesterol levels
- Bile acid binding agents
- Cholestyramine 4g daily – added to fruit juice (reduces side effects)
- Causes GI symptoms including constipation and foul smelling wind!
- Consider if above agents not working
- Poor evidence – they lower cholesterol but studies suggest they do NOT improve cardiovascular outcomes
- Thought to be more effective for triglyceride elevation
- Nicotinic acid
- 250mg BD with food
- Can increase up to 1000mg TDS
- Can cause gastric irritation, hot flushes and gout
Pregnancy often causes a transient elevated of LFTs. This is not thought to be of clinical significance and should only be treated if it does not resolve after delivery
Dietary agents affecting cholesterol
Various dietary agents have been suggested to lower cholesterol. These include:
- Fish oils – consuming fish at least twice a week has been shown to lower cholesterol
- Plant sterols – have also been shown to lower cholesterol
- Other compounds, such as vitamin E, garlic and lecithin are not supported by evidence
Familial hypercholesterolaemia – FH (aka familial hyperlipidaemia) is an inherited, autosomal dominant disorder. It is a common, but under diagnosed disorder, often encounter in general practice. It affects about 1 in 250 people, and 50% of all first degree relatives of an affected individual.
- Only about 10% of cases are formally identified
It results in massively elevated cholesterol levels from birth, which leads to the early development of cardiovascular disease.
- Cardiovascular disease risk is up to 25x greater than the general population
Patients may or may not present with the “textbook” signs of:
- Arcus senilis – white / grey / yellow ring around the margin of the cornea. Commonly seen in healthy older individuals, but pathological if found at age <45
- Tendon xanthomata – hard, non-tender lumps in tendons – most commonly the achilles tendon
- Xanethelasma – fatty deposits around the eyes
Occasionally (and I have seen it) when a blood sample is taken is can appear yellow and fatty in the test tube!
There are usually a strong family history of raised cholesterol and early onset cardiovascular disease. Early onset cardiovascular disease is defined as:
- Coronary artery disease in men aged <55
- Coronary artery disease in women aged <60
All FH patients should be follow-up annually to check the cholesterol levels and to investigate for any evidence of cardiovascular disease. Compliance, particularly in young asymptomatic patients can be difficult.
Diagnosing Familial Hypercholesterolaemia
Once other possible causes have been excluded – such as hypothyroidism, corticosteroid use, renal disease (nephrotic syndrome) and diabetes, then you can assess the patient for FH.
The Simon Broom diagnostic criteria suggest a diagnosis can be made with:
- TChol >7.5mmol/L AND
- Tendon xanthomata in patient or first or second degree relative OR
- DNA evidence of LDL receptor mutation
Other scoring systems (such as the Dutch Lipid Clinic Network Criteria – DLCNS) are also used – and are more complex. Online calculators are available. Genetic testing is not always required if a scoring system suggests a diagnosis of FH. If there is doubt over the diagnosis, then offer DNA testing. Also consider offering DNA testing to family members of a patient with confirmed FH particularly children of affected adults.
- Cascade screening is the term used to describe the screening process for relatives on an “index case” of familial hypercholesterolaemia
- It usually involves a genetics specialist, and discussion with family members about the sharing of confidential information, and the legal and ethical implications of sharing genetic information ith asymptomatic family members.
Elevated triglycerides, especially with otherwise normal lipid profile is strongly correlated to lifestyle factors. Triglycerides also vary more widely between a fasting and a non-fasting sample.
Elevated triglycerides may falsely alter the result of LDL (often making it appear falsely low)
If elevated to >5 mmol/L:
- Advise lifestyle changes, and re-check, ensuring a fasting sample
- Consider fibrates
- Familial Hyperlipidaemia - RACGP
- Murtagh’s General Practice. 6th Ed. (2015) John Murtagh, Jill Rosenblatt
- Hyperlidipaemia - patient.info
- Managing Lipids - NPS MedicineWise